2024 Highlights the Rollercoaster That Is Neuro - BioSpace
2024 saw highs and lows in neuroscience drug development, including FDA approval of BMS's Cobenfy for schizophrenia and Eli Lilly's donanemab for Alzheimer's, alongside failures like Sage Therapeutics' dalzanemdor in Parkinson's, Alzheimer's, and Huntington's. Despite setbacks, progress continues in treating intractable neurological diseases.
Highlighted Terms
dalzanemdorBristol Myers SquibbEisaiAmylyxdonanemabschizophreniaamyotrophic lateral sclerosisParkinson’s diseaseSarepta TherapeuticsQalsodyElevidysneurodegenerative diseasesLeqembiSage TherapeuticsRelyvrioEli LillyAduhelmBiogenDuchenne muscular dystrophyemraclidineHuntington’sAbbVieCobenfyAlzheimer’s
Related News
2024 Highlights the Rollercoaster That Is Neuro - BioSpace
2024 saw highs and lows in neuroscience drug development, including FDA approval of BMS's Cobenfy for schizophrenia and Eli Lilly's donanemab for Alzheimer's, alongside failures like Sage Therapeutics' dalzanemdor in Parkinson's, Alzheimer's, and Huntington's. Despite setbacks, progress continues in treating intractable neurological diseases.